Stuart Krost, MD
Pain Medicine · Lake Worth, FLNPI 1831143312
Payments from drug & device makers
Across 849 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Biotronik NRO, Inc.$8K
- Nevro Corp.$1K
- Collegium Pharmaceutical, Inc.$858
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$533
- Protega Pharmaceutials Inc$347
- plus $2K from 22 others
What the payments were for
- Travel & lodging$2771%
- Food & beverage$21,30298%
- Education$650%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 375 | $8,915 |
| Biotronik NRO, Inc. | 208 | $8,293 |
| Nevro Corp. | 61 | $1,091 |
| Collegium Pharmaceutical, Inc. | 51 | $858 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $533 |
| Protega Pharmaceutials Inc | 35 | $347 |
| Valinor Pharma, LLC | 17 | $270 |
| Forte Bio-pharma LLC | 13 | $225 |
| Eisai Inc. | 13 | $189 |
| Vertos Medical, Inc. | 3 | $144 |
| Pfizer | 7 | $144 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $91 |
| Idorsia Pharmaceuticals US Inc | 4 | $72 |
| Redhill Biopharma Inc. | 4 | $72 |
| Zyla Life Sciences, Inc. | 3 | $54 |
| UCB, Inc. | 1 | $40 |
| Boston Scientific | 1 | $39 |
| Hikma Pharmaceuticals USA | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| AstraZeneca | 2 | $26 |
| Orexo US, Inc. | 2 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Kaleo, Inc. | 1 | $21 |
| Masimo Corporation | 1 | $20 |
| Assertio Therapeutics, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Pernix Therapeutics Holdings, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$1,880
- Prospera$1,596
- Senza Spinal Cord Stimulation System$519
- BIOTRONIK$131
- mild Device Kit$101
How this compares
$21,643 in reported general payments places this provider in the 90th percentile of 596 pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 32 | $120,398 |
| MovantikNaloxegol Oxalate | 262 | $110,353 |
| RoxybondOxycodone Hcl | 80 | $109,169 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 3,234 | $100,597 |
| Xtampza ErOxycodone Myristate | 124 | $83,083 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,442 | $30,247 |
| OxycontinOxycodone Hcl | 31 | $27,722 |
| BelbucaBuprenorphine Hcl | 33 | $24,763 |
| Oxycodone Hcl | 1,500 | $23,864 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 143 | $20,275 |
| Naloxone Hcl | 255 | $20,251 |
| Morphine Sulfate ErMorphine Sulfate | 427 | $16,531 |
| Buprenorphine | 31 | $13,799 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $11,471 |
| Gabapentin | 1,086 | $9,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $72 | $110,353262 claims |
| Protega Pharmaceutials IncRoxybond | $347 | $109,16980 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $858 | $107,846157 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Morphine Sulfate, Buprenorphine Hcl | $37 | $41,674391 claims |
| Orexo US, Inc.Zubsolv | $24 | $11,47113 claims |
| PfizerLyrica | $144 | $6,40811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 pain medicine providers in Florida.
Other pain medicine in Lake Worth
- Anand PatelOrmond Beach$20.4M
- Julio PaezClermont$2.3M
- Joseph PergolizziNaples$2.1M
- Abel MurilloMiami$1.6M
- George MonluxPalm Coast$1.3M
- Ferdinand FormosoJacksonville$1M
- Cesar LassalleOrlando$1M
- Robert GuirguisTampa$895K
- Ashraf HannaClearwater$608K
- Peter MichaelCoral Gables$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.